3-Aminobenzamide: PARP-IN-1 Workflow Guide
2026-08-28
3-Aminobenzamide (PARP-IN-1) offers a practical chemical perturbation strategy for oxidative-stress, vascular, cardiac, renal, and host–virus studies. This guide connects concentration planning, assay controls, and troubleshooting with evidence-based PARP biology.
JC-1 Mitochondrial Membrane Potential Assay Guide
2026-08-27
Build a ratiometric mitochondrial membrane potential assay workflow for apoptosis studies, drug screening, and mechanistic follow-up in cancer models. The JC-1 Mitochondrial Membrane Potential Assay Kit combines red-to-green fluorescence analysis with a CCCP control and supports cellular, tissue, and purified mitochondrial samples.
BRD4–RAC1 Co-targeting in Breast Cancer
2026-08-27
This 2021 study identifies combined BRD4 and RAC1 inhibition as a context-dependent strategy that suppresses breast cancer growth, stemness, migration, and xenograft tumorigenesis across molecular subtypes. Its mechanistic contribution is the connection of BRD4–RAC1 blockade to the c-MYC–G9a–FTH1 axis and HDAC1-associated histone regulation, providing a framework for interpreting combination responses beyond simple viability loss.
Prenatal Nanoplastics and Vascular Lipid Dysregulation
2026-08-26
The reference study shows that prenatal and lactational exposure to polystyrene nanoplastics disrupts vascular lipid homeostasis in male mouse offspring and identifies the MAPK/ERK/UHRF1 axis as a mechanistic link. Its combination of developmental exposure, vascular smooth muscle cell experiments, pharmacological inhibition, and UHRF1 knockdown provides a useful framework for studying environmentally induced vascular remodeling.
Etoposide (VP-16): DNA Damage Research Guide
2026-08-26
Etoposide, also called VP-16, is a DNA topoisomerase II inhibitor that converts transient cleavage complexes into persistent DNA double-strand breaks. Its concentration-dependent activity, DMSO handling requirements, and links to ATM-mediated repair make it useful for DNA damage assay design and cancer chemotherapy research.
Dynasore Workflow for Dynamin-Dependent Endocytosis
2026-08-25
Dynasore provides a reversible, cell-permeable way to test whether dynamin-driven membrane fission controls uptake, vesicle recycling, or pathogen entry. This practical guide combines dose planning, cargo-uptake assays, virology workflows, and troubleshooting to help distinguish endocytic blockade from solvent, viability, or downstream signaling artifacts.
Dopamine, cAMP/PKA, and Osteoclast Differentiation
2026-08-25
Wang and colleagues identify a D2R-dependent cAMP/PKA/CREB cascade through which dopamine suppresses osteoclast differentiation. Their rescue experiments place reduced CREB phosphorylation downstream of dopamine-mediated cAMP/PKA inhibition, providing a mechanistic framework for studying neural regulation of bone remodeling.
HyperScript RT SuperMix for qPCR in URSA
2026-08-24
HyperScript RT SuperMix for qPCR is a premixed reverse-transcription reagent for two-step qRT-PCR and gene expression analysis. Its engineered reverse transcriptase, mixed-primer design, and high RNA-input capacity address structurally complex or low-concentration RNA templates while requiring validation for each assay.
Balsalazide Disodium in Colon-Targeted Assays
2026-08-23
Balsalazide disodium is more than a 5-ASA prodrug: it is a useful platform for linking bacterial activation, colon localization, and inflammatory readouts. This guide translates radiolabeling evidence into practical decisions for inflammation research, immunology assays, and inflammatory bowel disease models.
BX795: Practical PDK1 Inhibitor Assay Workflows
2026-08-22
BX795 is a versatile PDK1 inhibitor for connecting kinase biochemistry with cancer-cell response and innate immune signaling. This workflow-focused guide shows how to separate pathway inhibition, proliferation arrest, and cell death while managing BX795’s additional TBK1 and IKKε activity.
Cdk1–PP2A Control of Atypical E2F Degradation
2026-08-21
The reference preprint identifies a Cdk1–PP2A molecular switch that times APC/C-dependent degradation of E2F7 and E2F8 during the mitosis-to-G1 transition. Its combination of cellular and cell-free systems links phosphorylation-state control to orderly remodeling of E2F transcriptional activity and provides a framework for studying phosphorylation-dependent protein turnover.
METTL14–SMN Methylation Controls m6A Homeostasis
2026-08-21
The reference study identifies SMN as an arginine methylation-dependent interaction partner of METTL14, linking the m6A writer complex to spinal muscular atrophy-associated molecular defects. Its cell and mouse data connect impaired m6A deposition on DNA repair transcripts with genome-stress sensitivity and abnormal early hematopoiesis, providing a framework for studying RNA modification and genome stability.
DOTAP Workflows for Nucleic Acid Delivery
2026-08-20
DOTAP offers a controllable route to complex DNA, RNA, and antisense oligonucleotides for transient expression, gene silencing, and lipid nanoparticle optimization. This guide connects practical transfection design with the immune-metabolic logic of a recent nano-granulated zoledronate study while clearly separating established evidence from formulation recommendations.
Nebivolol Hydrochloride: Reading Negative TOR Data
2026-08-20
Nebivolol hydrochloride is a potent β1-adrenoceptor antagonist for receptor-focused cardiovascular studies. This article explains how a 2025 drug-sensitized yeast study places its negative TOR result in the correct assay and mechanistic context.
LLC-PK1-MDR1 Model for BBB Permeability
2026-08-19
Hu and colleagues developed a Transwell surrogate blood–brain barrier model that combines LLC-PK1-MOCK/MDR1 cells with permeability, efflux, and recovery measurements. Its key advance is the use of bafilomycin A1 to correct lysosomal trapping, improving the relationship between in vitro transport data and in vivo unbound brain distribution.
459 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page